BACKGROUND: The coexistence of breast cancer (BC) and acute myeloid leukemia (AML) has rarely been reported. Considering the fatality of AML, the management of this condition is based on treating the AML immediately while putting BC treatment on hold. CASE REPORT: Here, we report a synchronous occurrence of BC and AML. Prognostic factors for both BC and AML were determined by genomic and molecular evaluation. The evaluation for AML showed a relatively good prognosis, and we simultaneously conducted treatment for AML and BC. The patient has survived for more than 3 years, which makes this the case with the longest survival reported. CONCLUSION: In patients with BC and AML, it is essential to determine the prognosis through a genomic and molecular evaluation. For a certain group of patients whose prognosis of AML is good, simultaneous or initial treatment of BC before treatment of AML may be appropriate.
BACKGROUND: The coexistence of breast cancer (BC) and acute myeloid leukemia (AML) has rarely been reported. Considering the fatality of AML, the management of this condition is based on treating the AML immediately while putting BC treatment on hold. CASE REPORT: Here, we report a synchronous occurrence of BC and AML. Prognostic factors for both BC and AML were determined by genomic and molecular evaluation. The evaluation for AML showed a relatively good prognosis, and we simultaneously conducted treatment for AML and BC. The patient has survived for more than 3 years, which makes this the case with the longest survival reported. CONCLUSION: In patients with BC and AML, it is essential to determine the prognosis through a genomic and molecular evaluation. For a certain group of patients whose prognosis of AML is good, simultaneous or initial treatment of BC before treatment of AML may be appropriate.
Authors: Iveta Sarova; Jana Brezinova; Zuzana Zemanova; Dagmar Bystricka; Zdenek Krejcik; Petr Soukup; Jan Vydra; Jaroslav Cermak; Anna Jonasova; Kyra Michalova Journal: Genes Chromosomes Cancer Date: 2013-04-12 Impact factor: 5.006
Authors: Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield Journal: Blood Date: 2009-10-30 Impact factor: 22.113
Authors: Bryan Linggi; Carsten Müller-Tidow; Louis van de Locht; Ming Hu; John Nip; Hubert Serve; Wolfgang E Berdel; Bert van der Reijden; Dawn E Quelle; Janet D Rowley; John Cleveland; Joop H Jansen; Pier Paolo Pandolfi; Scott W Hiebert Journal: Nat Med Date: 2002-06-24 Impact factor: 53.440
Authors: P P Mishra; M Mahapatra; V P Choudhry; R Saxena; H Pati; A Dixit; R Anupama; J Bhattacharya; T Chatterjee; P Dutta Journal: Ann Hematol Date: 2004-02-13 Impact factor: 3.673
Authors: Thorsten Klampfl; Jelena D Milosevic; Ana Puda; Andreas Schönegger; Klaudia Bagienski; Tiina Berg; Ashot S Harutyunyan; Bettina Gisslinger; Elisa Rumi; Luca Malcovati; Daniela Pietra; Chiara Elena; Matteo Giovanni Della Porta; Lisa Pieri; Paola Guglielmelli; Christoph Bock; Michael Doubek; Dana Dvorakova; Nada Suvajdzic; Dragica Tomin; Natasa Tosic; Zdenek Racil; Michael Steurer; Sonja Pavlovic; Alessandro M Vannucchi; Mario Cazzola; Heinz Gisslinger; Robert Kralovics Journal: PLoS One Date: 2013-10-16 Impact factor: 3.240
Authors: Michaela Aubele; Gert Auer; Herbert Braselmann; Jörg Nährig; Horst Zitzelsberger; Leticia Quintanilla-Martinez; Jan Smida; Axel Walch; Heinz Höfler; Martin Werner Journal: Anal Cell Pathol Date: 2002 Impact factor: 2.916